Solventum Co. (NYSE:SOLV) Stake Raised by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC grew its holdings in shares of Solventum Co. (NYSE:SOLV) by 27.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,317 shares of the company’s stock after purchasing an additional 1,580 shares during the period. Sequoia Financial Advisors LLC’s holdings in Solventum were worth $483,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in SOLV. Atria Investments Inc boosted its holdings in Solventum by 93.2% during the third quarter. Atria Investments Inc now owns 11,699 shares of the company’s stock worth $816,000 after buying an additional 5,644 shares in the last quarter. Victory Capital Management Inc. lifted its position in shares of Solventum by 137.3% during the 3rd quarter. Victory Capital Management Inc. now owns 53,589 shares of the company’s stock valued at $3,736,000 after acquiring an additional 31,007 shares during the last quarter. Oppenheimer & Co. Inc. bought a new stake in shares of Solventum during the 3rd quarter worth $315,000. CIBC Asset Management Inc grew its holdings in shares of Solventum by 7.9% in the 3rd quarter. CIBC Asset Management Inc now owns 19,291 shares of the company’s stock worth $1,345,000 after acquiring an additional 1,408 shares during the last quarter. Finally, Natixis Advisors LLC raised its position in shares of Solventum by 271.4% during the third quarter. Natixis Advisors LLC now owns 47,616 shares of the company’s stock worth $3,320,000 after purchasing an additional 34,797 shares during the period.

Solventum Trading Up 0.3 %

NYSE SOLV opened at $75.38 on Wednesday. The firm’s fifty day simple moving average is $74.77 and its 200-day simple moving average is $71.38. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $85.92. The company has a market capitalization of $13.04 billion and a PE ratio of 27.41.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on SOLV. Morgan Stanley lifted their price target on Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 5th. Bank of America boosted their price target on shares of Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, February 26th. Piper Sandler raised their price objective on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research note on Friday, February 28th. Mizuho boosted their target price on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, March 3rd. Finally, Wells Fargo & Company lifted their price target on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $79.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.